DDInter1921 DDInter1676
Vasopressin (arginine-vasopressin or antidiuretic hormone) is a nonapeptide primarily produced in the hypothalamus that exhibits diverse physiological functions related to diuresis, hemodynamic modulation, and behaviour.[A110, A111, A112, A113, A228008] Vasopressin is very similar to oxytocin, differing in the third and eighth amino acids. Despite a wide variety of functions, exogenous vasopressin is primarily used to control blood pressure during systemic shock by increasing vasoconstriction and renal fluid reuptake by acting through V<sub>1</sub> and V<sub>2</sub> cellular receptors.[A228008, A228013, A228018, L31413] The vasopressive effect of posterior pituitary gland extracts was noted in 1895, while vasopressin itself was not purified until 1951. It has been used for
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Vasopressin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Vasopressin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bicalutamide
Vasopressin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Goserelin
Vasopressin {u} may lead to a major life threatening interaction when taken with {v} Fingolimod
Vasopressin may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide
Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Goserelin
Vasopressin may lead to a major life threatening interaction when taken with Fingolimod